HUTCHMED
Tracked across 3 events · 20 articles · First seen Apr 09, 2026 · Last active Jul 14, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: HUTCHMED announced positive results from its pivotal Phase II study of fanregratinib for intrahepatic cholangiocarcinoma, which is a significant milestone for the company's drug development pipeline and could lead to regulatory approval and commercialization.
Jun 24, 2026 · 6 articles
Regulatory
Impact: HUTCHMED, a biopharmaceutical company, received conditional approval from the China — National Medical Products Administration for its drug ORPATHYS (savolitinib) for gastric cancer treatment in China. This marks the third approved indication for ORPATHYS in China and validates HUTCHMED's R&D platform.
Jul 02, 2026 · 6 articles
Business
Impact: Mentioned as a collaborator with AstraZeneca on Orpathys, not directly impacted.
Jul 14, 2026 · 8 articles
ERGEN INTELLIGENCE
Track HUTCHMED live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard